Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1
The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is...
Saved in:
Published in | Journal of virological methods Vol. 163; no. 2; pp. 505 - 508 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier B.V
01.02.2010
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable “in–house” genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An “in-house” assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000–1.6 million RNA copies/ml). The “in-house” assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq™ HIV-1 Genotyping kit. The “in-house” assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The “in house” sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the “in-house” assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated “in-house” drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. |
---|---|
AbstractList | The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable "in-house" genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An "in-house" assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000-1.6 million RNA copies/ml). The "in-house" assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq HIV-1 Genotyping kit. The "in-house" assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The "in house" sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the "in-house" assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated "in-house" drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable “in–house” genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An “in-house” assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000–1.6 million RNA copies/ml). The “in-house” assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq™ HIV-1 Genotyping kit. The “in-house” assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The “in house” sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the “in-house” assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated “in-house” drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. The introduction of antiretroviral therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable “in–house” genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An “in-house” assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1,000->1.6million RNA copies/ml). The “in-house” assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq TM HIV-1 Genotyping kit. The “in-house” assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The “in house” sequences were 99.2%) homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the “in-house” assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated “in-house” drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. |
Author | Karita, Etienne Kaleebu, Pontiano Wallis, Carole L. Papathanasopoulos, Maria A. Lakhi, Shabir Stevens, Gwynn Kamali, Anatoli Wit, Tobias F. Rinke de Bekker, Linda-Gail Anzala, Omu Stevens, Wendy Sanders, Eduard |
AuthorAffiliation | 8 Internation AIDS Vaccine Initiative Johannesburg, South Africa 11 National Health Laboratory Services (NHLS), Johannesburg., South Africa 2 Zambia Emory HIV Research Project (ZEHRP), Lusaka, Zambia 3 Project San Francisco (PSF) , Kigali, Rwanda 7 Desmond Tutu HIV Foundation, Cape Town, South Africa 1 Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa 6 Kenya AIDS Vaccine Initiative, Nairobi, Kenya 9 Linking African and Asian Societies for an Enhanced Response to HIV/AIDS (LAASER) 10 PharmAccess Foundation, Amsterdam, The Netherlands 5 Centre for Geographic Medicine Research-Coast (CGMRC), Kenya Medical Research Institute (KEMRI) - Kilifi, Kenya 4 MRC/UVRI Uganda Virus Research Unit on AIDS, , Uganda |
AuthorAffiliation_xml | – name: 2 Zambia Emory HIV Research Project (ZEHRP), Lusaka, Zambia – name: 8 Internation AIDS Vaccine Initiative Johannesburg, South Africa – name: 5 Centre for Geographic Medicine Research-Coast (CGMRC), Kenya Medical Research Institute (KEMRI) - Kilifi, Kenya – name: 1 Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa – name: 9 Linking African and Asian Societies for an Enhanced Response to HIV/AIDS (LAASER) – name: 10 PharmAccess Foundation, Amsterdam, The Netherlands – name: 7 Desmond Tutu HIV Foundation, Cape Town, South Africa – name: 6 Kenya AIDS Vaccine Initiative, Nairobi, Kenya – name: 11 National Health Laboratory Services (NHLS), Johannesburg., South Africa – name: 3 Project San Francisco (PSF) , Kigali, Rwanda – name: 4 MRC/UVRI Uganda Virus Research Unit on AIDS, , Uganda |
Author_xml | – sequence: 1 givenname: Carole L. surname: Wallis fullname: Wallis, Carole L. email: cwallis@mweb.co.za organization: Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa – sequence: 2 givenname: Maria A. surname: Papathanasopoulos fullname: Papathanasopoulos, Maria A. organization: Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa – sequence: 3 givenname: Shabir surname: Lakhi fullname: Lakhi, Shabir organization: Zambia Emory HIV Research Project (ZEHRP), Lusaka, Zambia – sequence: 4 givenname: Etienne surname: Karita fullname: Karita, Etienne organization: Project San Francisco (PSF), Kigali, Rwanda – sequence: 5 givenname: Anatoli surname: Kamali fullname: Kamali, Anatoli organization: MRC/UVRI Uganda Virus Research Unit on AIDS, Uganda – sequence: 6 givenname: Pontiano surname: Kaleebu fullname: Kaleebu, Pontiano organization: MRC/UVRI Uganda Virus Research Unit on AIDS, Uganda – sequence: 7 givenname: Eduard surname: Sanders fullname: Sanders, Eduard organization: Centre for Geographic Medicine Research-Coast (CGMRC), Kenya Medical Research Institute (KEMRI), Kilifi, Kenya – sequence: 8 givenname: Omu surname: Anzala fullname: Anzala, Omu organization: Kenya AIDS Vaccine Initiative, Nairobi, Kenya – sequence: 9 givenname: Linda-Gail surname: Bekker fullname: Bekker, Linda-Gail organization: Desmond Tutu HIV Foundation, Cape Town, South Africa – sequence: 10 givenname: Gwynn surname: Stevens fullname: Stevens, Gwynn organization: Internation AIDS Vaccine Initiative Johannesburg, South Africa – sequence: 11 givenname: Tobias F. Rinke de surname: Wit fullname: Wit, Tobias F. Rinke de organization: PharmAccess Foundation, The Netherlands – sequence: 12 givenname: Wendy surname: Stevens fullname: Stevens, Wendy organization: Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22464020$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19917318$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1DAURi1URKeFV6iyQawS_JNx4g2iVJRWqsQG2FqOfT3jURIPdjJo3p47naHAqqtYusdfvutzQc7GOAIhV4xWjDL5flNtdiHFAaaKU6oqxirK2AuyYG2jSqra-owsEJR4FvU5uch5QyldNkK8IudMKdYI1i4IXHsfkzNdD0UYy3WcMxRmnEKCKUX8hekLl-ZVkSCHPJnR4jhnsy9-hWldrGJ0xRYSZgyPszAW2LTMczftt1B8Ku7uf5TsNXnpTZ_hzel7Sb7ffv52c1c-fP1yf3P9UNql4FMJdau4N9zZunVLZ6VTwlDLWC2xbuulk9B2VHovampdvfRdgzsJ6l1rjRTiknw45m7nbgBnYZxwAb1NYTBpr6MJ-v_JGNZ6FXeaK8GVZBjw7hSQ4s8Z8qSHkC30vRkBn0Y3NVbhSonnSSEkuuCHTHkkbYo5J_BPfRjVB5l6o__I1AeZmjGNMvHi1b_b_L12sofA2xNgsjW9T6gg5CeO81rWlFPkPh45wLffBUg62wCoy6FmO2kXw3NdfgPAxcTP |
CODEN | JVMEDH |
CitedBy_id | crossref_primary_10_1371_journal_pone_0105790 crossref_primary_10_3390_v13061125 crossref_primary_10_1186_s12977_014_0122_8 crossref_primary_10_1016_j_jviromet_2014_03_001 crossref_primary_10_1002_jmv_23202 crossref_primary_10_1371_journal_pone_0028184 crossref_primary_10_1371_journal_pone_0034708 crossref_primary_10_1371_journal_pone_0087441 crossref_primary_10_1016_j_jcv_2012_01_018 crossref_primary_10_1093_cid_ciac804 crossref_primary_10_1016_j_jcv_2012_01_010 crossref_primary_10_1089_aid_2020_0049 crossref_primary_10_1093_jac_dkw218 crossref_primary_10_1016_j_jviromet_2013_01_001 crossref_primary_10_1128_AAC_01805_16 crossref_primary_10_1128_JCM_00118_13 crossref_primary_10_1128_JCM_00756_15 crossref_primary_10_1093_cid_ciu314 crossref_primary_10_1128_JCM_01478_10 crossref_primary_10_1093_infdis_jiw219 crossref_primary_10_1097_QAI_0b013e31829308f8 crossref_primary_10_1111_j_1469_0691_2010_03300_x crossref_primary_10_1016_j_jviromet_2024_114939 crossref_primary_10_1371_journal_pone_0117176 crossref_primary_10_1016_j_jviromet_2013_08_015 crossref_primary_10_1371_journal_pone_0118145 crossref_primary_10_1371_journal_pone_0032144 crossref_primary_10_1016_S1473_3099_11_70149_9 crossref_primary_10_1007_s00705_011_0982_3 crossref_primary_10_1093_cid_ciac755 crossref_primary_10_1371_journal_pone_0097067 crossref_primary_10_1093_cid_ciac875 crossref_primary_10_1186_s13104_016_2101_8 crossref_primary_10_1371_journal_pone_0131541 crossref_primary_10_1371_journal_pone_0238027 crossref_primary_10_3851_IMP1985 crossref_primary_10_1002_jmv_24162 crossref_primary_10_1089_aid_2011_0136 crossref_primary_10_1016_j_meegid_2020_104243 crossref_primary_10_2217_fvl_13_21 crossref_primary_10_5372_1905_7415_0502_032 crossref_primary_10_1089_aid_2010_0030 crossref_primary_10_1089_aid_2009_0281 crossref_primary_10_1128_AAC_02101_19 crossref_primary_10_4236_aim_2018_85023 crossref_primary_10_1002_jia2_25849 crossref_primary_10_1093_jac_dkv500 crossref_primary_10_1177_2040206618762985 crossref_primary_10_1371_journal_pone_0224292 crossref_primary_10_1111_tmi_12741 crossref_primary_10_1097_QAI_0000000000003027 crossref_primary_10_1097_QAI_0b013e318227fc34 |
Cites_doi | 10.1128/JCM.41.4.1594-1599.2003 10.1086/589297 10.7326/0003-4819-124-7-199604010-00006 10.1086/587109 10.1128/JCM.42.6.2711-2717.2004 10.1097/QCO.0b013e3280109ff1 10.1097/QAI.0b013e3181bc478b |
ContentType | Journal Article |
Copyright | 2009 Elsevier B.V. 2015 INIST-CNRS 2009 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2009 Elsevier B.V. – notice: 2015 INIST-CNRS – notice: 2009 Elsevier B.V. All rights reserved. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 H94 5PM |
DOI | 10.1016/j.jviromet.2009.11.011 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Virology and AIDS Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1879-0984 |
EndPage | 508 |
ExternalDocumentID | 10_1016_j_jviromet_2009_11_011 19917318 22464020 S0166093409004819 |
Genre | Validation Studies Evaluation Studies Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | South Africa |
GeographicLocations_xml | – name: South Africa |
GrantInformation_xml | – fundername: International AIDS Vaccine Initiative grantid: GPH-G-00-01-0004-00 – fundername: PharmAccess Studies – fundername: Dutch Ministry of Foreign Affairs grantid: 12454 – fundername: Netherlands Organization for Scientific Research/Netherlands Foundation – fundername: NIAID NIH HHS grantid: U19 AI053217 – fundername: PHS HHS grantid: GPH-G-00-01-0004-00 – fundername: NIAID NIH HHS grantid: 1U19 AI53217-01 – fundername: NIAID NIH HHS grantid: U19 AI053217-08 – fundername: Medical Research Council grantid: MC_U950080938 – fundername: Medical Research Council grantid: MC_U950080930 |
GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29L 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LCYCR LUGTX M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSZ T5K VH1 WUQ XFK Y6R ZGI ~G- ~KM ABPIF ABPTK IQODW AAHBH AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 7U9 H94 5PM |
ID | FETCH-LOGICAL-c532t-e4892fa2dc48d5dc6d93a0c11461738f6d6e8b06ff340cd45fb700530fd8ca633 |
IEDL.DBID | AIKHN |
ISSN | 0166-0934 |
IngestDate | Tue Sep 17 21:26:38 EDT 2024 Wed Dec 04 15:21:02 EST 2024 Fri Oct 25 10:15:45 EDT 2024 Fri Dec 06 04:44:47 EST 2024 Sat Sep 28 07:45:41 EDT 2024 Sun Oct 22 16:08:05 EDT 2023 Fri Feb 23 02:34:16 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Antiretroviral drug resistance HIV-1 subtype C Affordable Mutation profile Antiretroviral agent HIV-1 virus Retroviridae Method Lentivirus Virus Resistance Antiviral Human immunodeficiency virus Mutation Subtype |
Language | English |
License | CC BY 4.0 2009 Elsevier B.V. All rights reserved. https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c532t-e4892fa2dc48d5dc6d93a0c11461738f6d6e8b06ff340cd45fb700530fd8ca633 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 ObjectType-Undefined-1 content type line 23 ObjectType-Undefined-3 ObjectType-Feature-1 |
OpenAccessLink | https://europepmc.org/articles/pmc2932961?pdf=render |
PMID | 19917318 |
PQID | 733618721 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2932961 proquest_miscellaneous_744612993 proquest_miscellaneous_733618721 crossref_primary_10_1016_j_jviromet_2009_11_011 pubmed_primary_19917318 pascalfrancis_primary_22464020 elsevier_sciencedirect_doi_10_1016_j_jviromet_2009_11_011 |
PublicationCentury | 2000 |
PublicationDate | 2010-02-01 |
PublicationDateYYYYMMDD | 2010-02-01 |
PublicationDate_xml | – month: 02 year: 2010 text: 2010-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington – name: Netherlands |
PublicationTitle | Journal of virological methods |
PublicationTitleAlternate | J Virol Methods |
PublicationYear | 2010 |
Publisher | Elsevier B.V Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier |
References | Eshleman, Hackett, Swanson, Cunningham, Drews, Brennan, Devare, Zekeng, Kaptue, Marlowe (bib3) 2004; 42 Wallis, C.L., Mellors, J.W., Venter, W.D.F., Sanne, I., Stevens, W., 2009. Varied drug resistance profiles following first-line regimen failure in the South Africa Antiretroviral Program. J. AIDS Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes, Mellors, Pillay, Yeni, Jacobsen, Richman (bib5) 2008; 47 Kuritzkes, Grant, Feorino, Griswold, Hoover, Young, Day, Lloyd, Reid, Morgan, Winslow (bib7) 2003; 41 Bennett (bib1) 2006; 19 Lee, Espin, Turner, Griswold, Kahn (bib8) 1999; 39 International Treatment Preparedness Coalition, 2007. Missing the target number 4: time is running out to end AIDS-treatment and prevention for all!. Marconi, Sunpath, Lu, Gordon, Koranteng-Apeagyei, Hampton, Carpenter, Giddy, Ross, Holst, Losina, Walker, Kuritzkes (bib10) 2008; 46 Fauci, Pantaleo, Stanley, Weissman (bib4) 1996; 124 Loubsher, Sherman, Chezzi, Jones, Cohen, Puren, Morris (bib9) 2004; 9 . Engelbrecht, Van Zyl, Claassen, Laten, Jacobs, Preiser (bib2) 2007 18419495 - Clin Infect Dis. 2008 May 15;46(10):1589-97 18549313 - Clin Infect Dis. 2008 Jul 15;47(2):266-85 18441382 - Top HIV Med. 2008 Apr-May;16(1):62-8 17075338 - Curr Opin Infect Dis. 2006 Dec;19(6):607-14 15184457 - J Clin Microbiol. 2004 Jun;42(6):2711-7 8607594 - Ann Intern Med. 1996 Apr 1;124(7):654-63 12682150 - J Clin Microbiol. 2003 Apr;41(4):1594-9 Eshleman (10.1016/j.jviromet.2009.11.011_bib3) 2004; 42 Hirsch (10.1016/j.jviromet.2009.11.011_bib5) 2008; 47 10.1016/j.jviromet.2009.11.011_bib6 Kuritzkes (10.1016/j.jviromet.2009.11.011_bib7) 2003; 41 10.1016/j.jviromet.2009.11.011_bib11 Fauci (10.1016/j.jviromet.2009.11.011_bib4) 1996; 124 Loubsher (10.1016/j.jviromet.2009.11.011_bib9) 2004; 9 Engelbrecht (10.1016/j.jviromet.2009.11.011_bib2) 2007 Marconi (10.1016/j.jviromet.2009.11.011_bib10) 2008; 46 Lee (10.1016/j.jviromet.2009.11.011_bib8) 1999; 39 Bennett (10.1016/j.jviromet.2009.11.011_bib1) 2006; 19 |
References_xml | – start-page: 528 year: 2007 ident: bib2 article-title: A sensitive in-house RT-PCR assay for the assessment of HIV-1 Antiretroviral drug resistance publication-title: SA-AIDS contributor: fullname: Preiser – volume: 41 start-page: 1594 year: 2003 end-page: 1599 ident: bib7 article-title: Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system publication-title: J. Clin. Microbiol. contributor: fullname: Winslow – volume: 9 start-page: S145 year: 2004 ident: bib9 article-title: Characterization of Nevirapine resistance mutations using RT-PCR and DNA sequencing methods in a mother-infant cohort following single dose Nevirapine publication-title: Antivir. Ther. contributor: fullname: Morris – volume: 39 start-page: 462 year: 1999 ident: bib8 article-title: Genotyping of HIV-1 drug-resistance: comparison between in-house procedure and visible genetics Trugene[Tm] HIV-1 assay publication-title: Abstr. Intersci. Conf. Antimicrob. Agents Chemother. contributor: fullname: Kahn – volume: 46 start-page: 1589 year: 2008 end-page: 1597 ident: bib10 article-title: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal publication-title: S. Afr. Clin. Infect. Dis. contributor: fullname: Kuritzkes – volume: 19 start-page: 607 year: 2006 end-page: 614 ident: bib1 article-title: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world publication-title: Curr. Opin. Infect. Dis. contributor: fullname: Bennett – volume: 42 start-page: 2711 year: 2004 end-page: 2717 ident: bib3 article-title: Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains publication-title: J. Clin. Microbiol. contributor: fullname: Marlowe – volume: 47 start-page: 266 year: 2008 end-page: 285 ident: bib5 article-title: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel publication-title: Clin. Infect. Dis. contributor: fullname: Richman – volume: 124 start-page: 654 year: 1996 end-page: 663 ident: bib4 article-title: Immunopathogenic mechanisms of HIV infection publication-title: Ann. Intern. Med. contributor: fullname: Weissman – start-page: 528 year: 2007 ident: 10.1016/j.jviromet.2009.11.011_bib2 article-title: A sensitive in-house RT-PCR assay for the assessment of HIV-1 Antiretroviral drug resistance publication-title: SA-AIDS contributor: fullname: Engelbrecht – volume: 41 start-page: 1594 year: 2003 ident: 10.1016/j.jviromet.2009.11.011_bib7 article-title: Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.41.4.1594-1599.2003 contributor: fullname: Kuritzkes – volume: 47 start-page: 266 year: 2008 ident: 10.1016/j.jviromet.2009.11.011_bib5 article-title: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel publication-title: Clin. Infect. Dis. doi: 10.1086/589297 contributor: fullname: Hirsch – volume: 9 start-page: S145 year: 2004 ident: 10.1016/j.jviromet.2009.11.011_bib9 article-title: Characterization of Nevirapine resistance mutations using RT-PCR and DNA sequencing methods in a mother-infant cohort following single dose Nevirapine publication-title: Antivir. Ther. contributor: fullname: Loubsher – volume: 124 start-page: 654 year: 1996 ident: 10.1016/j.jviromet.2009.11.011_bib4 article-title: Immunopathogenic mechanisms of HIV infection publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-124-7-199604010-00006 contributor: fullname: Fauci – ident: 10.1016/j.jviromet.2009.11.011_bib6 – volume: 46 start-page: 1589 year: 2008 ident: 10.1016/j.jviromet.2009.11.011_bib10 article-title: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal publication-title: S. Afr. Clin. Infect. Dis. doi: 10.1086/587109 contributor: fullname: Marconi – volume: 42 start-page: 2711 year: 2004 ident: 10.1016/j.jviromet.2009.11.011_bib3 article-title: Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.42.6.2711-2717.2004 contributor: fullname: Eshleman – volume: 19 start-page: 607 year: 2006 ident: 10.1016/j.jviromet.2009.11.011_bib1 article-title: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world publication-title: Curr. Opin. Infect. Dis. doi: 10.1097/QCO.0b013e3280109ff1 contributor: fullname: Bennett – volume: 39 start-page: 462 year: 1999 ident: 10.1016/j.jviromet.2009.11.011_bib8 article-title: Genotyping of HIV-1 drug-resistance: comparison between in-house procedure and visible genetics Trugene[Tm] HIV-1 assay publication-title: Abstr. Intersci. Conf. Antimicrob. Agents Chemother. contributor: fullname: Lee – ident: 10.1016/j.jviromet.2009.11.011_bib11 doi: 10.1097/QAI.0b013e3181bc478b |
SSID | ssj0005733 |
Score | 2.1909266 |
Snippet | The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected... The introduction of antiretroviral therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals.... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 505 |
SubjectTerms | Affordable Anti-Retroviral Agents - pharmacology Antiretroviral drug resistance Antiviral agents Automation Biological and medical sciences DNA Primers - genetics Drug Resistance, Viral Fundamental and applied biological sciences. Psychology Genes, Viral Genotype HIV-1 - drug effects HIV-1 - genetics HIV-1 - isolation & purification HIV-1 subtype C Human immunodeficiency virus 1 Humans Microbial Sensitivity Tests - economics Microbial Sensitivity Tests - methods Microbiology Mutation profile Reverse Transcriptase Polymerase Chain Reaction - methods RNA, Viral - genetics RNA, Viral - isolation & purification Sensitivity and Specificity South Africa Techniques used in virology Virology |
Title | Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1 |
URI | https://dx.doi.org/10.1016/j.jviromet.2009.11.011 https://www.ncbi.nlm.nih.gov/pubmed/19917318 https://search.proquest.com/docview/733618721 https://search.proquest.com/docview/744612993 https://pubmed.ncbi.nlm.nih.gov/PMC2932961 |
Volume | 163 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbtswEB1kQYECRdG96mLw0Ctja6Okoxs0cGogh7ZpcxMokUxsoLKRyIdc8u15Y0pxXHQ59CRAoihwhhy-R81C9EG7qAbnymRt0kQmWVVIDS4kndVpYqsak2jtIHuiJqfJ57P0bIcO-1gYdqvsbL-36Wtr3d0ZdtIcLmez4VeAFQU-DoKyTnpS7NI-tiP-V7s_Pp5OTjaeHpmvKI_2kl-4Fyg8P5hzONlP2_rUlZzQMwz_tEc9WuorSM75khe_w6S_ulbe26uOntDjDmSKsR_HU9qxzTN64MtOXj8nO3bs0s5BU2LWyAuQfysgYUii5RMG9CjM5epcgIozvIRMBDC2vhZ8aivOFwsjlpuAA_QhmkUjr1YVH-iKj2Jy_F2GL-j06NO3w4nsyi3IOo2jVtokLyKnI1MnuUlNrUwR61HNYcthFudOGWXzaqScg8xrk6SuyngNj5zJa63i-CXt4Wv2NQl0AMZeYcE74BsLUJS6POV6oAaPlA1o2Au4XPqsGmXvbjYve5VwicwCFKWESgIqej2UW_OjhOn_57uDLcXdfZKT6TF_Dkj0miyxuviXiW4shF9yssgwB0v-SxMQaoCmIg7oldf9ZkgA3xmMZkDZ1qy4a8C5vbefNLOLdY5voLCoUOGb_xj2W3roXR3Y9-Yd7bWXK_seCKqtBrR7cBMOunXC1-mXH9Nb6ugfwg |
link.rule.ids | 230,314,780,784,885,4502,24116,27924,27925,45585,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VVggkhHgVAqX4wNXs5p0cl4oqS8teaFFvVhLb7a5EdtVmD_33fLNOul0E7aHXxLHlGXv8fc48iD6XNqjBuVJZ6ziSUVrlsgQXktaUcWSqGoto5SA7SYrT6PtZfLZFB30sDLtVdrbf2fSVte6eDDppDhbT6eAnwEoCPg6Cskp6kj-iHaCBFEt7ZzQ-KiZrT4_UVZRHe8kf3AoUnn2ZcTjZb9O61JWc0NP3_3dGPVuUV5CcdSUv_oVJ_3atvHVWHb6g5x3IFCM3j5e0ZZpX9NiVnbx-TWZk2aWdg6bEtJEXIP9GQMKQRMs3DOhR6MvluQAVZ3gJmQhg7PJa8K2tOJ_PtVisAw7Qh2jmjbxaVnyhK76KYvxL-m_o9PDbyUEhu3ILso7DoJUmyvLAloGuo0zHuk50HpbDmsOW_TTMbKITk1XDxFrIvNZRbKuU9_DQ6qwukzDcpW2MZt6RQAdg7BU2vAW-MQBFsc1irgeq8SoxHg16AauFy6qhenezmepVwiUyc1AUBZV4lPd6UBvrQ8H03_vt_obibobkZHrMnz0SvSYVdhf_MikbA-ErThbpZ2DJdzQBoQZoykOP3jrdr6cE8J3CaHqUbqyKmwac23vzTTO9WOX4BgoL8sR__4Bpf6InxcmPY3U8nhx9oKfO7YH9cPZou71cmo9AU2213-2WP_lJIBw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Affordable+in-house+antiretroviral+drug+resistance+assay+with+good+performance+in+non-subtype+B+HIV-1&rft.jtitle=Journal+of+virological+methods&rft.au=Wallis%2C+Carole+L.&rft.au=Papathanasopoulos%2C+Maria+A.&rft.au=Lakhi%2C+Shabir&rft.au=Karita%2C+Etienne&rft.date=2010-02-01&rft.issn=0166-0934&rft.eissn=1879-0984&rft.volume=163&rft.issue=2&rft.spage=505&rft.epage=508&rft_id=info:doi/10.1016%2Fj.jviromet.2009.11.011&rft_id=info%3Apmid%2F19917318&rft.externalDBID=PMC2932961 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0166-0934&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0166-0934&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0166-0934&client=summon |